Envisia Therapeutics has released an interim analysis on the second cohort of its ENV515 (travoprost XR) Phase 2 trial, which involves patients with glaucoma.
In the study, those who took a single administration of the product saw a clinically meaningful reduction in intraocular pressure (IOP) over the 11-month evaluation period.
"A clinically meaningful reduction in IOP over the initial 11 months indicates that ENV515 has the potential to become a once a year therapy for glaucoma patients," Envisia President Benjamin Yerxa said in a statement. "We continue to enroll patients into the next cohort of the study where we are studying ENV515 dose levels that have the potential to demonstrate a duration-of-action longer than the current 11 months."
The company noted that ENV515 also demonstrated an IOP lowering effect that compares to both prestudy topical prostaglandin analogs and in-study topical timolol maleate 0.5 percent ophthalmic solution.
According to Envisia, Yerxa presented the data at the Glaucoma 360 event in San Francisco, an annual meeting put together by the Glaucoma Research Foundation. Glaucoma is the leading cause of preventable blindness; Envisia notes that this is often due to patients not taking once-daily eye drops.
"These eleven-month results demonstrate that ENV515 could achieve once a year dosing frequency which would be a very meaningful improvement over currently available daily therapies," Dr. Thomas Walters, the lead investigator for the ENV515 Phase 2 trial, said.
Alerts Sign-up